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A B S T R A C T
The patients with uveitic glaucoma are at high risk for failure following drainage surgery because of young age of
these patients, preoperative long-term control of inflammation and postoperative complications. Twenty-two trabe-
culectomies performed in 22 patients with uveitic glaucoma were retrospectively evaluated to analyze the effect of
intraoperative application of mitomycin C (MMC). Success rates, postoperative levels of intraocular pressure (IOP)
and postoperative complications were studied. After a mean follow-up of 10.6 months (range, 5–28 months), 15 pa-
tients (68.2%) achieved IOP of 21mmHg or less without antiglaucoma medications. There were statistically significant
reduction in IOP postoperatively during the period studied (p<0.001). Early postoperative complications included cho-
rioidal detachment (9.1%), shallow anterior chamber (9.1%), hyphema (13.6%), macular edema (4.5%) and raised IOP
(27.3%). Late postoperative complications included exacerbation of uveitis (4.5%), macular edema (4.5%), cataract
(22.7%) and raised IOP (31.8 %). The eyes with raised IOP needed additional antiglaucoma medication. The results of
this retrospective and uncontrolled study suggest that intraoperative application of MMC may be a good option for en-
hancement of short-term trabeculectomy success rates in patients with uveitic glaucoma.
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Introduction
Glaucoma is frequent and potentially vision threat-
ening complication of intraocular inflammation. It af-
fects 20–50% of patients and is characterized by a
multifactor pathogenesis. The various mechanisms in-
volved include obstruction of the trabecular meshwork
by cellular debris and protein, trabeculitis, angle-clo-
sure from peripheral anterior synechiae, pupillary block
from posterior synechiae, angle neovascularisation and
steroid induced. Glaucoma associated with uveitis may
not be controlled my medical therapy alone and may re-
quire surgical treatment. Patients with uveitic glau-
coma are at high risk for failure following the surgery.
In addition to the uveitis the young age of these patients
may contribute to the high risk. The various surgical ap-
proaches described include trabeculectomy, trabecule-
ctomy with antimetabolites and drainage devices. Re-
gardless of the type of surgical intervention chosen,
timing of the operation is critical and maximum control
of the intraocular inflammation for at least two months
prior to surgery is important for the successful control of
glaucoma and favorable long term visual outcome.
To improve the success rate of trabeculectomy in pa-
tients with uveitic glaucoma, antimetabolite therapy in
association with trabeculectomy has been used for 15
years. Postoperative subconjunctival injection of 5-fluo-
rouracil (5-FU), triamcinolone or, more recently, intra-
operative application of mitomycin C (MMC) have been
reported to improve the outcome of filtering surgery1–7.
Because of corneal epithelial toxicity and the need for
frequent postoperative subconjunctival injections, 5-FU
has been replaced by topical application of MMC, with
good surgical results reported for secondary glaucoma.
In a multicentered study of 19 eyes with uveitic glau-
coma that underwent trabeculectomy with MMC, 18
eyes (95%) were successful with intraocular pressure
(IOP) < 21 mmHg, with one or no medications, after a
follow-up of 8.5 months6. The success rate after trabe-
culectomy enhanced with antimetabolites in patients
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with uveitis varies from 51% to 90%. Wright8 and asso-
ciates and Prata6 and associates reported absolute suc-
cess rates of 62% and 75%, respectively, in 24 eyes with
uveitis that underwent trabeculectomy with intraopera-
tive application of mitomycin C. Most studies of patients
with uveitis, who have undergone glaucoma surgery
with antimetabolites, have analyzed results at 1 to 2
years after trabeculectomy, but the long term success
rate has been documented by use of drainage devi-
ces9–11.
The purpose of this study was to evaluate the out-
come of trabeculectomy with MMC in patients with uve-
itic glaucoma refractory to maximally tolerated anti-
glaucomatous medical therapy.
Patients and Methods
This is a retrospective study on 22 eyes of 22 patients
who had undergone trabeculectomy with mitomycin C
for uncontrolled IOP secondary to intraocular inflam-
mation between January 2000 and March 2004. The fol-
lowing variables were studied: age, sex, preoperative
duration of increased IOP, number and category of anti-
glaucoma medications used preoperatively and postop-
erative early and late complications during the extend-
ed follow-up period.
Eyes that had previous conjunctival or intraocular
surgery or laser trabeculoplastics were excluded from
the study. Twenty-two eyes of 22 patients with various
types of uveitis were included in the study. The mean
age (± SE) for all patients was 42.1±6.9 (range, 32 to 58
years); eight patients were male and fourteen were fe-
male. The duration of glaucoma before trabeculectomy
was 4 to 6 months. All patients had uncontrolled IOP
despite maximally tolerated antiglaucomatous medical
therapy (Table 1).
The trabeculectomies were all performed by one sur-
geon in the following manner after informed written
consent was obtained: retrobulbar and peripheral facial
blocks were given using 2% lydocaine and 0.75% bupi-
vacaine, mixed 50:50. A limbal-based conjunctival flap
was created starting 7 to 8 mm behind the limbus. A 3 x
3 mm scleral flap, 2/3 of the scleral thickness was made
and after that mitomycin was applied in exposition of 3
minutes (0,5 mg of mitomycin was diluted in 20 ml
physiological liquid). After that Descemet´s Kelly punch
was use to excise approximately 1 x 2 mm of anterior
chamber angle tissue. Three to five 10-0 nylon sutures
were used to suture the scleral flap to the surrounding
sclera. The conjunctiva was closed using a running,
lockong 9.0 Vicryl suture.
All eyes received dexamethasone eyedrops every two
hours while the patient was awake and dexamethasone
ointment before sleeping, starting the day after surgery.
Seven to ten days after surgery, the administration of
corticosteroids was decreased to four times a day and
the ointment was discontinued. The frequency of dexa-
methasone drops was than decreased by one daily dose
per week.
When describing results, parameters of descriptive
statistics were used. For the qualitative data, absolute
and relative frequencies were used, and for the quanti-
tative data mean, standard error, median and range.
Changes in IOP level, between the two single measure-
ments, were tested according to the Mann-Whitney U
test. Values when p<0.005 were considered statistically
significant.
Results
A mean follow-up was 10.6 months (range, 5–28
months). During that period there were three main vis-
its of patients. The first visit was the day after surgery,
the second one a month after surgery and the third one
6 months or later after surgery.
The mean level of preoperative IOP (± SE) was 31±
0,7 mm Hg. In postoperative follow-up the level of IOP
(± SE) was 16.1 ± 1.4 in the first visit, 17.5 ± 1.3 in the
second visit and 16.3 ± 1.1 in the third visit (Table 2).
Statistical analysis demonstrated a statistically signifi-
cant reduction in IOP postoperatively during the period
studied (p<0.001)
Early postoperative complications are shown in Ta-
ble 3. A day after surgery, two patients developed cho-
riodal detachment, two shallow anterior chamber, and
three postoperative hyphema, which vanished very
soon. On the first postoperative day, in 15 patients there
were no complications. A month after surgery there

































PREOPERATIVE AND POSTOPERATIVE FOLLOW OF
INTRAOCULAR PRESSURE (mmHg)
X SE Median Range
Preoperative 31 0.7 30 26–42
1st visit 16.1 1.4 14 4–26
2nd visit 17.5 1.3 15.5 8–30
3rd visit 16.3 1.1 14.5 8–25
Operation: 1st visit p<0.001; Mann-Whitney U test
Operation: 2nd visit p<0.001; Operation: 3rd visit p<0.001
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were no cases of choroidal detachments or shallow ante-
rior chambers, but 6 patients had increased level of IOP
that needed additional medical therapy.
On the third visit there were no complications at all
in 14 patients, but some complications such as macular
edema and exacerbation of uveitis were noticed. Seven
eyes developed increased level of IOP and in five eyes
cataract was developed (Table 4).
Discussion and Conclusion
The surgical management of glaucoma secondary to
intraocular inflammation can be complex and challeng-
ing problem because of numerous mechanisms involved
in its pathogenesis. The reported evidence appears con-
flicting, as some studies have suggested that these pa-
tients may be at high risk for failure after drainage sur-
gery1,5,12, yet others have reported a high success rate,
at least after short follow-up8,13. This is also indicated
by the diversity of surgical approaches, including wound
modulation with antimetabolites and drainage devices
6,8,14. The purpose of this study was to assess the out-
come of trabeculectomy with mitomycin C in patients
with uveitic glaucoma refractory to medical therapy.
Wright8 and associates and Prata6 and associates re-
ported absolute success rates of 62% and 75%, respec-
tively, in 24 eyes with uveitis that underwent trabecu-
lectomy with intraoperative application of mitomycin C.
During the period studied 62%8 and 75 %6 eyes achieved
an IOP of 21 mmHg or less without antiglaucoma medi-
cations. The same IOP level with one antiglaucoma
medication was achieved in 16.6% eyes. Ceballos15 and
associates reported absolute success rates of 78% in first
year and 62% in second year after trabeculectomy with
mitomycin C.
In our study, seven of twenty-two (32 %) patients de-
veloped an increased IOP level (IOP > 21 mmHg) six
months or later after glaucoma surgery. As for the level
of IOP is concerned, in 68% of our patients, the results of
our satisfactory has been achieved in postoperative fol-
low up period of 10.6 months. Those results almost cor-
relate with the results above mentioned authors.
Improvement in the pattern of uveitis after trabecu-
lectomy with or without antimetabolites compared with
the preoperative period was obvious in many patients.
Weinreb16 reported postoperative improvement of the
inflammation and reduction in the topical and systemic
corticosteroids in four of six patients who underwent fil-
tering surgery with postoperative subconjunctival 5-FU
for inflammatory glaucoma. Jampel1 and associates re-
ported no severe inflammatory exacerbations in the im-
mediate postoperative period in 12 uveitic eyes that un-
derwent trabeculectomy with 5-FU. Ophir and Ticho
also reported remission of anterior uveitis over 12
months by repeat subconjunctival injection of 5-FU in
three patients who underwent trabeculectomy for glau-
coma because of anterior uveitis17. Improvement of uve-
itis after trabeculectomy is not related to the hypothesis
of a beneficial effect of the antimetabolite on the intra-
ocular inflammation1,16,17. Postoperative inflammation
or reactivation of uveitis has been reported to occur in
5.2% to 31.1% of cases of uveitic glaucoma5,6. This inci-
dence can be lowered by treating the patients with pre
and postoperative corticosteroids18. In our study, there
was only one patient with exacerbation of uveitis on the
third visit.
Postoperative hyphema has not been reported to be a
significant problem in trabeculectomy for uveitic glau-
coma. Prata and associates reported postoperative hy-
phema in 4.2 % cases6. In our study there were 13.6%
patients with hyphema in early postoperative period.
Postoperative complications such as chorioidal detach-
ment, hypotony, postoperative shallow anterior cham-
ber, wound leak and macular edema are higher in eyes
with uveitic glaucoma since adjunctive treatment with
5-FU, mitomycin C or a drainage device is more com-
monly used in patients with uveitic glaucoma. Results
of this study such as 9.1% of chorioidal detachment,
9.1% of shallow anterior chamber and 4.5% of macular
edema are in agreement with previous observations6,15,19.
Cataract progression is very common after filtration
surgery for uveitis glaucoma. In one study5 90% (9/10) of
the phakic eyes with uveitic glaucoma that underwent
trabeculectomy with antimetabolites had progression of
the cataract and seven of these eyes needed surgery. In
other study15 51.6% phakic patients developed new cat-
aracts or had progression existing cataracts and re-
quired cataract extraction. In our study, 5 patients
(22.7%) developed new cataracts. Late postoperative
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TABLE 3
FREQUENCIES OF EARLY POSTOPERATIVE COMPLICATIONS
Complications
1st visit 2nd visit
N % n %
No complications 15 68.2 16 72.7
Chorioidal detachment 2 9.1 – –
Shallow anterior chamber 2 9.1 – –
Hyphema 3 13.6 – –
Raised IOP – – 6 27.3
Macular edema – – 1 4.5
TABLE 4




No complications 14 63.6
Exacerbation of uveitis 1 4.5
Cataract 5 22.7
Raised IOP 7 31.8
Macular edema 1 4.5
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endophthalmitis can occur in patients treated with mi-
tomycin C. Bleb infection with conjunctival discharge is
typically seen in postoperative endophthalmitis associ-
ated with filtering surgery20. This complication is rare
and unnoticed in our study, fortunately. The patients
with uveitic glaucoma are at high risk of failure follow-
ing drainage surgery because of young age of these pa-
tients, preoperative long-term control of inflammation
and postoperative complications.
In conclusion, the results of this retrospective and
uncontrolled study suggest that intraoperative applica-
tion of MMC may be a good option for enhancement of
short-term trabeculectomy success rates in cases of uve-
itic glaucoma.
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TRABEKULOTOMIJA S MITOMICINOM C KOD UVEITI^KOG GLAUKOMA
S A @ E T A K
Rizik za neuspje{an ishod operativnog drena`nog zahvata kod bolesnika s uveiti~kim glaukomom vrlo je visok
zbog mlade `ivotne dobi ovih bolesnika, dugotrajne preoperativne kontrole upale i postoperativnih komplikacija. Iz-
vedeno je 22 trabekulektomije u 22 bolesnika sa uveiti~kim glaukomom i retrospektivno evaluirano kako bi se anali-
zirao u~inak intraoperativne primjene mitomicina C. Prou~avana je uspje{nost operativnog zahvata, postoperativna
razina intraokularnog tlaka (IOT) i postoperativne komplikacije. Nakon srednjeg vremena pra}enja od 10.6 mjeseci
(raspon, 5–28 mjeseci), kod 15 (68.2%) bolesnika postignut je IOT od 21 mmHg ili manji bez antiglaukomskih lije-
kova. Postoji statisti~ki zna~ajno sni`enje IOT tijekom postoperativnog pra}enja bolesnika (p<0,001). Rane postope-
rativne komplikacije uklju~ivale su: odignu}e `ilnice (9,1%), plitku prednju sobicu (9,1%), hifemu (13,6%), edem makule
(4,5%) i povi{eni IOT (27,3%). Kasne postoperativne komplikacije uklju~ivale su: eksacerbaciju uveitisa (4,5%), ma-
kularni edem (4,5%), kataraktu (22,7%) i povi{eni IOT (31,8%). O~i s povi{enim IOT-om trebale su dodatnu anti-
glaukomsku terapiju. Rezultati ove retrospektivne studije sugeriraju da intraoperativna primjena mitomicina C pos-
pje{uje ishod trabekulektomije u bolesnika s uveiti~kim glaukomom u kratkom postoperativnom pra}enju bolesnika.
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